2. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays. 2004;26(12):1351–62. [PubMed] [Google Scholar]
3. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769–83. [PubMed] [Google Scholar]
5. Blundell TL, Cutfield JF, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA. The crystal structure of rhombohedral 2 zinc insulin. Cold Spring Harb Symp Quant Biol. 1972;36:233–41. [PubMed] [Google Scholar]
6. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA. Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes. 1972;21(2 Suppl):492–505. [PubMed] [Google Scholar]
7. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA, Vijayan M. Atomic positions in rhombohedral 2-zinc insulin crystals. Nature. 1971;231(5304):506–11. [PubMed] [Google Scholar]
8. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Hubbard RE, Isaacs NW, Reynolds CD, Sakabe K, Sakabe N, Vijayan M. The structure of 2 Zn pig insulin crystals at 1.5 A resolution. Philos Trans R Soc London. 1988;B319:369–456. [PubMed] [Google Scholar]
9. Smith GD, Pangborn WA, Blessing RH. The structure of T6 human insulin at 1. 0 A resolution. Acta Crystallogr D Biol Crystallogr. 2003;59(Pt 3):474–82. [PubMed] [Google Scholar]
10. Dodson GG, Whittingham JL. Insulin and related proteins - structure to function and pharmacology. Springer; New York: 2002. Insulin: sequence, structure and function - a story of surprises; pp. 29–39. [Google Scholar]
11. Pullen RA, Lindsay DG, Wood SP, Tickle IJ, Blundell TL, Wollmer A, Krail G, Brandenburg D, Zahn H, Gliemann J, Gammeltoft S. Receptor-binding region of insulin. Nature. 1976;259(5542):369–73. [PubMed] [Google Scholar]
12. Hua QX, Shoelson SE, Kochoyan M, Weiss MA. Receptor binding redefined by a structural switch in a mutant human insulin. Nature. 1991;354(6350):238–41. [PubMed] [Google Scholar]
13. Ludvigsen S, Olsen HB, Kaarsholm NC. A structural switch in a mutant insulin exposes key residues for receptor binding. J Mol Biol. 1998;279(1):1–7. [PubMed] [Google Scholar]
14. Kwok SC, Steiner DF, Rubenstein AH, Tager HS. Identification of a point mutation in the human insulin gene giving rise to a structurally abnormal insulin (insulin Chicago) Diabetes. 1983;32(9):872–5. [PubMed] [Google Scholar]
15. Shoelson S, Haneda M, Blix P, Nanjo A, Sanke T, Inouye K, Steiner D, Rubenstein A, Tager H. Three mutant insulins in man. Nature. 1983;302(5908):540–3. [PubMed] [Google Scholar]
16. Shoelson S, Fickova M, Haneda M, Nahum A, Musso G, Kaiser ET, Rubenstein AH, Tager H. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. Proc Natl Acad Sci U S A. 1983;80(24):7390–4. [PMC free article] [PubMed] [Google Scholar]
17. Kobayashi M, Ohgaku S, Iwasaki M, Maegawa H, Shigeta Y, Inouye K. Characterization of [LeuB-24]-and [LeuB-25]-insulin analogues. Receptor binding and biological activity. Biochem J. 1982;206(3):597–603. [PMC free article] [PubMed] [Google Scholar]
18. Kobayashi M, Ohgaku S, Iwasaki M, Maegawa H, Shigeta Y, Inouye K. Supernormal insulin: [D-PheB24]-insulin with increased affinity for insulin receptors. Biochem Biophys Res Commun. 1982;107(1):329–36. [PubMed] [Google Scholar]
19. Nanjo K, Sanke T, Miyano M, Okai K, Sowa R, Kondo M, Nishimura S, Iwo K, Miyamura K, Given BD. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin. J Clin Invest. 1986;77(2):514–9. [PMC free article] [PubMed] [Google Scholar]
20. Wollmer A, Rannefeld B, Johansen BR, Hejnaes KR, Balschmidt P, Hansen FB. Phenol-promoted structural transformation of insulin in solution. Biol Chem Hoppe Seyler. 1987;368(8):903–11. [PubMed] [Google Scholar]
21. Ogawa H, Burke GT, Chanley JD, Katsoyannis PG. Effect of N-methylation of selected peptide bonds on the biological activity of insulin. [2-N-methylisoleucine-A]insulin and [3-N-methylvaline-A]insulin. Int J Pept Protein Res. 1987;30(4):460–73. [PubMed] [Google Scholar]
22. Schwartz G, Katsoyannis PG. Synthesis of des(tetrapeptide B(1–4)) and des(pentapeptide B(1–5)) human insulins. Two biologically active analogues. Biochemistry. 1978;17(21):4550–6. [PubMed] [Google Scholar]
23. Nakagawa SH, Tager HS. Implications of invariant residue LeuB6 in insulin-receptor interactions. J Biol Chem. 1991;266(18):11502–9. [PubMed] [Google Scholar]
24. Chan SJ, Seino S, Gruppuso PA, Schwartz R, Steiner DF. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. Proc Natl Acad Sci U S A. 1987;84(8):2194–7. [PMC free article] [PubMed] [Google Scholar]
25. Gruppuso PA, Gorden P, Kahn CR, Cornblath M, Zeller WP, Schwartz R. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med. 1984;311(10):629–34. [PubMed] [Google Scholar]
26. Schwartz GP, Burke GT, Katsoyannis PG. A superactive insulin: [B10-aspartic acid]insulin(human) Proc Natl Acad Sci U S A. 1987;84(18):6408–11. [PMC free article] [PubMed] [Google Scholar]
27. Egea PF, Stroud RM, Walter P. Targeting proteins to membranes: structure of the signal recognition particle. Curr Opin Struct Biol. 2005;15(2):213–20. [PubMed] [Google Scholar]
28. Chan SJ, Keim P, Steiner DF. Cell-free synthesis of rat preproinsulins: characterization and partial amino acid sequence determination. Proc Natl Acad Sci U S A. 1976;73(6):1964–8. [PMC free article] [PubMed] [Google Scholar]
29. Lomedico PT, Chan SJ, Steiner DF, Saunders GF. Immunological and chemical characterization of bovine preproinsulin. J Biol Chem. 1977;252(22):7971–8. [PubMed] [Google Scholar]
30. Patzelt C, Labrecque AD, Duguid JR, Carroll RJ, Keim PS, Heinrikson RL, Steiner DF. Detection and kinetic behavior of preproinsulin in pancreatic islets. Proc Natl Acad Sci U S A. 1978;75(3):1260–4. [PMC free article] [PubMed] [Google Scholar]
31. Huang XF, Arvan P. Intracellular transport of proinsulin in pancreatic beta-cells. Structural maturation probed by disulfide accessibility. J Biol Chem. 1995;270(35):20417–23. [PubMed] [Google Scholar]
32. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell. 1987;48(5):899–907. [PubMed] [Google Scholar]
33. Steiner DFKW, Clark JL, Oyer PE, Rubenstein A. The biosynthesis of insulin. In: Steiner DF, Freinkel N, editors. Handbook of physiology—Section 7 Endocrinology I. Williams & Wilkins; Baltimore: 1972. pp. 175–198. [Google Scholar]
34. Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF. Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. J Biol Chem. 1990;265(8):4173–6. [PubMed] [Google Scholar]
35. Poitout V, Hagman D, Stein R, Artner I, Robertson RP, Harmon JS. Regulation of the insulin gene by glucose and fatty acids. J Nutr. 2006;136(4):873–6. [PMC free article] [PubMed] [Google Scholar]
36. Giddings SJ, Chirgwin J, Permutt MA. Effects of glucose on proinsulin messenger RNA in rats in vivo. Diabetes. 1982;31(7):624–9. [PubMed] [Google Scholar]
37. Welsh M, Nielsen DA, MacKrell AJ, Steiner DF. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. J Biol Chem. 1985;260(25):13590–4. [PubMed] [Google Scholar]
38. Knopp RH, Bergelin RO, Wahl PW, Walden CE. Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes. 1985;34 (Suppl 2):71–7. [PubMed] [Google Scholar]
39. Knoch KP, Meisterfeld R, Kersting S, Bergert H, Altkruger A, Wegbrod C, Jager M, Saeger HD, Solimena M. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab. 2006;3(2):123–34. [PubMed] [Google Scholar]
40. Soares MB, Schon E, Henderson A, Karathanasis SK, Cate R, Zeitlin S, Chirgwin J, Efstratiadis A. RNA-mediated gene duplication: the rat preproinsulin I gene is a functional retroposon. Mol Cell Biol. 1985;5(8):2090–103. [PMC free article] [PubMed] [Google Scholar]
41. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985;315(6015):115–22. [PubMed] [Google Scholar]
42. Bucchini D, Ripoche MA, Stinnakre MG, Desbois P, Lores P, Monthioux E, Absil J, Lepesant JA, Pictet R, Jami J. Pancreatic expression of human insulin gene in transgenic mice. Proc Natl Acad Sci U S A. 1986;83(8):2511–5. [PMC free article] [PubMed] [Google Scholar]
43. Crowe DT, Tsai MJ. Mutagenesis of the rat insulin II 5′-flanking region defines sequences important for expression in HIT cells. Mol Cell Biol. 1989;9(4):1784–9. [PMC free article] [PubMed] [Google Scholar]
44. Edlund T, Walker MD, Barr PJ, Rutter WJ. Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5′ flanking elements. Science. 1985;230(4728):912–6. [PubMed] [Google Scholar]
45. Melloul D, Ben-Neriah Y, Cerasi E. Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci U S A. 1993;90(9):3865–9. [PMC free article] [PubMed] [Google Scholar]
46. Sharma A, Stein R. Glucose-induced transcription of the insulin gene is mediated by factors required for beta-cell-type-specific expression. Mol Cell Biol. 1994;14(2):871–9. [PMC free article] [PubMed] [Google Scholar]
47. Whelan J, Poon D, Weil PA, Stein R. Pancreatic beta-cell-type-specific expression of the rat insulin II gene is controlled by positive and negative cellular transcriptional elements. Mol Cell Biol. 1989;9(8):3253–9. [PMC free article] [PubMed] [Google Scholar]
48. Dean PM. Ultrastructural morphometry of the pancreatic-cell. Diabetologia. 1973;9(2):115–9. [PubMed] [Google Scholar]
49. Howell SL. The mechanism of insulin secretion. Diabetologia. 1984;26(5):319–27. [PubMed] [Google Scholar]
50. Hay CW, Docherty K. Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes. 2006;55(12):3201–13. [PubMed] [Google Scholar]
51. Steiner DF, Chan SJ, Welsh JM, Kwok SC. Structure and evolution of the insulin gene. Annu Rev Genet. 1985;19:463–84. [PubMed] [Google Scholar]
52. German M, Ashcroft S, Docherty K, Edlund H, Edlund T, Goodison S, Imura H, Kennedy G, Madsen O, Melloul D. The insulin gene promoter. A simplified nomenclature. Diabetes. 1995;44(8):1002–4. [PubMed] [Google Scholar]
53. Gehring WJ, Affolter M, Burglin T. Homeodomain proteins. Annu Rev Biochem. 1994;63:487–526. [PubMed] [Google Scholar]
54. Trainor PA, Krumlauf R. Hox genes, neural crest cells and branchial arch patterning. Curr Opin Cell Biol. 2001;13(6):698–705. [PubMed] [Google Scholar]
55. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. Embo J. 1993;12(11):4251–9. [PMC free article] [PubMed] [Google Scholar]
56. Leonard J, Peers B, Johnson T, Ferreri K, Lee S, Montminy MR. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol. 1993;7(10):1275–83. [PubMed] [Google Scholar]
57. Miller CP, McGehee RE, Jr, Habener JF. IDX-1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. Embo J. 1994;13(5):1145–56. [PMC free article] [PubMed] [Google Scholar]
58. German MS, Wang J, Chadwick RB, Rutter WJ. Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex. Genes Dev. 1992;6(11):2165–76. [PubMed] [Google Scholar]
59. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature. 1990;344(6269):879–82. [PubMed] [Google Scholar]
60. Peshavaria M, Gamer L, Henderson E, Teitelman G, Wright CV, Stein R. XIHbox 8, an endoderm-specific Xenopus homeodomain protein, is closely related to a mammalian insulin gene transcription factor. Mol Endocrinol. 1994;8(6):806–16. [PubMed] [Google Scholar]
61. Petersen HV, Serup P, Leonard J, Michelsen BK, Madsen OD. Transcriptional regulation of the human insulin gene is dependent on the homeodomain protein STF1/IPF1 acting through the CT boxes. Proc Natl Acad Sci U S A. 1994;91(22):10465–9. [PMC free article] [PubMed] [Google Scholar]
62. Peers B, Leonard J, Sharma S, Teitelman G, Montminy MR. Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol Endocrinol. 1994;8(12):1798–806. [PubMed] [Google Scholar]
63. Guz Y, Montminy MR, Stein R, Leonard J, Gamer LW, Wright CV, Teitelman G. Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development. 1995;121(1):11–8. [PubMed] [Google Scholar]
64. Wu KL, Gannon M, Peshavaria M, Offield MF, Henderson E, Ray M, Marks A, Gamer LW, Wright CV, Stein R. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. Mol Cell Biol. 1997;17(10):6002–13. [PMC free article] [PubMed] [Google Scholar]
65. Chawengsaksophak K, James R, Hammond VE, Kontgen F, Beck F. Homeosis and intestinal tumours in Cdx2 mutant mice. Nature. 1997;386(6620):84–7. [PubMed] [Google Scholar]
66. Thor S, Ericson J, Brannstrom T, Edlund T. The homeodomain LIM protein Isl-1 is expressed in subsets of neurons and endocrine cells in the adult rat. Neuron. 1991;7(6):881–9. [PubMed] [Google Scholar]
67. Leonard J, Serup P, Gonzalez G, Edlund T, Montminy M. The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. Proc Natl Acad Sci U S A. 1992;89(14):6247–51. [PMC free article] [PubMed] [Google Scholar]
68. Wang M, Drucker DJ. The LIM domain homeobox gene isl-1 is a positive regulator of islet cell-specific proglucagon gene transcription. J Biol Chem. 1995;270(21):12646–52. [PubMed] [Google Scholar]
69. Wang M, Drucker DJ. Activation of amylin gene transcription by LIM domain homeobox gene isl-1. Mol Endocrinol. 1996;10(3):243–51. [PubMed] [Google Scholar]
70. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 1997;385(6613):257–60. [PubMed] [Google Scholar]
71. Shieh SY, Tsai MJ. Cell-specific and ubiquitous factors are responsible for the enhancer activity of the rat insulin II gene. J Biol Chem. 1991;266(25):16708–14. [PubMed] [Google Scholar]
72. Zhao L, Cissell MA, Henderson E, Colbran R, Stein R. The RIPE3b1 activator of the insulin gene is composed of a protein(s) of approximately 43 kDa, whose DNA binding activity is inhibited by protein phosphatase treatment. J Biol Chem. 2000;275(14):10532–7. [PubMed] [Google Scholar]
73. Shieh SY, Stellrecht CM, Tsai MJ. Molecular characterization of the rat insulin enhancer-binding complex 3b2. Cloning of a binding factor with putative helicase motifs. J Biol Chem. 1995;270(37):21503–8. [PubMed] [Google Scholar]
74. Kataoka K, Han SI, Shioda S, Hirai M, Nishizawa M, Handa H. MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene. J Biol Chem. 2002;277(51):49903–10. [PubMed] [Google Scholar]
75. Matsuoka TA, Zhao L, Artner I, Jarrett HW, Friedman D, Means A, Stein R. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol Cell Biol. 2003;23(17):6049–62. [PMC free article] [PubMed] [Google Scholar]
76. Olbrot M, Rud J, Moss LG, Sharma A. Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc Natl Acad Sci U S A. 2002;99(10):6737–42. [PMC free article] [PubMed] [Google Scholar]
77. Matsuoka TA, Artner I, Henderson E, Means A, Sander M, Stein R. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc Natl Acad Sci U S A. 2004;101(9):2930–3. [PMC free article] [PubMed] [Google Scholar]
78. Zhao L, Guo M, Matsuoka TA, Hagman DK, Parazzoli SD, Poitout V, Stein R. The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem. 2005;280(12):11887–94. [PubMed] [Google Scholar]
79. Hagman DK, Hays LB, Parazzoli SD, Poitout V. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem. 2005;280(37):32413–8. [PMC free article] [PubMed] [Google Scholar]
80. Harmon JS, Stein R, Robertson RP. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem. 2005;280(12):11107–13. [PubMed] [Google Scholar]
81. Zhang C, Moriguchi T, Kajihara M, Esaki R, Harada A, Shimohata H, Oishi H, Hamada M, Morito N, Hasegawa K, Kudo T, Engel JD, Yamamoto M, Takahashi S. MafA is a key regulator of glucose-stimulated insulin secretion. Mol Cell Biol. 2005;25(12):4969–76. [PMC free article] [PubMed] [Google Scholar]
82. Knepel W, Vallejo M, Chafitz JA, Habener JF. The pancreatic islet-specific glucagon G3 transcription factors recognize control elements in the rat somatostatin and insulin-I genes. Mol Endocrinol. 1991;5(10):1457–66. [PubMed] [Google Scholar]
83. Sander M, Neubuser A, Kalamaras J, Ee HC, Martin GR, German MS. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev. 1997;11(13):1662–73. [PubMed] [Google Scholar]
84. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature. 1997;386(6623):399–402. [PubMed] [Google Scholar]
85. Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic beta-cell development. Mol Cells. 2004;18(3):289–94. [PubMed] [Google Scholar]
86. German MS, Moss LG, Wang J, Rutter WJ. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol. 1992;12(4):1777–88. [PMC free article] [PubMed] [Google Scholar]
87. Whelan J, Cordle SR, Henderson E, Weil PA, Stein R. Identification of a pancreatic beta-cell insulin gene transcription factor that binds to and appears to activate cell-type-specific expression: its possible relationship to other cellular factors that bind to a common insulin gene sequence. Mol Cell Biol. 1990;10(4):1564–72. [PMC free article] [PubMed] [Google Scholar]
88. Buskin JN, Hauschka SD. Identification of a myocyte nuclear factor that binds to the muscle-specific enhancer of the mouse muscle creatine kinase gene. Mol Cell Biol. 1989;9(6):2627–40. [PMC free article] [PubMed] [Google Scholar]
89. Ephrussi A, Church GM, Tonegawa S, Gilbert W. B lineage--specific interactions of an immunoglobulin enhancer with cellular factors in vivo. Science. 1985;227(4683):134–40. [PubMed] [Google Scholar]
90. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51(6):987–1000. [PubMed] [Google Scholar]
91. Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. Embo J. 1989;8(3):701–9. [PMC free article] [PubMed] [Google Scholar]
92. Brennan TJ, Olson EN. Myogenin resides in the nucleus and acquires high affinity for a conserved enhancer element on heterodimerization. Genes Dev. 1990;4(4):582–95. [PubMed] [Google Scholar]
93. Cabrera CV, Martinez-Arias A, Bate M. The expression of three members of the achaete-scute gene complex correlates with neuroblast segregation in Drosophila. Cell. 1987;50(3):425–33. [PubMed] [Google Scholar]
94. Naya FJ, Stellrecht CM, Tsai MJ. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev. 1995;9(8):1009–19. [PubMed] [Google Scholar]
95. Lee JE, Hollenberg SM, Snider L, Turner DL, Lipnick N, Weintraub H. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science. 1995;268(5212):836–44. [PubMed] [Google Scholar]
96. Cordle SR, Henderson E, Masuoka H, Weil PA, Stein R. Pancreatic beta-cell-type-specific transcription of the insulin gene is mediated by basic helix-loop-helix DNA-binding proteins. Mol Cell Biol. 1991;11(3):1734–8. [PMC free article] [PubMed] [Google Scholar]
97. German MS, Blanar MA, Nelson C, Moss LG, Rutter WJ. Two related helix-loop-helix proteins participate in separate cell-specific complexes that bind the insulin enhancer. Mol Endocrinol. 1991;5(2):292–9. [PubMed] [Google Scholar]
98. Peyton M, Moss LG, Tsai MJ. Two distinct class A helix-loop-helix transcription factors, E2A and BETA1, form separate DNA binding complexes on the insulin gene E box. J Biol Chem. 1994;269(41):25936–41. [PubMed] [Google Scholar]
99. Naya FJ, Huang HP, Qiu Y, Mutoh H, DeMayo FJ, Leiter AB, Tsai MJ. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. Genes Dev. 1997;11(18):2323–34. [PMC free article] [PubMed] [Google Scholar]
100. Huang HP, Chu K, Nemoz-Gaillard E, Elberg D, Tsai MJ. Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. Mol Endocrinol. 2002;16(3):541–51. [PubMed] [Google Scholar]
101. Sander M, Griffen SC, Huang J, German MS. A novel glucose-responsive element in the human insulin gene functions uniquely in primary cultured islets. Proc Natl Acad Sci U S A. 1998;95(20):11572–7. [PMC free article] [PubMed] [Google Scholar]
102. Boam DS, Clark AR, Docherty K. Positive and negative regulation of the human insulin gene by multiple trans-acting factors. J Biol Chem. 1990;265(14):8285–96. [PubMed] [Google Scholar]
103. Le Lay J, Stein R. Involvement of PDX-1 in activation of human insulin gene transcription. J Endocrinol. 2006;188(2):287–94. [PubMed] [Google Scholar]
104. Pino MF, Ye DZ, Linning KD, Green CD, Wicksteed B, Poitout V, Olson LK. Elevated glucose attenuates human insulin gene promoter activity in INS-1 pancreatic beta-cells via reduced nuclear factor binding to the A5/core and Z element. Mol Endocrinol. 2005;19(5):1343–60. [PubMed] [Google Scholar]
105. Inagaki N, Maekawa T, Sudo T, Ishii S, Seino Y, Imura H. c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci U S A. 1992;89(3):1045–9. [PMC free article] [PubMed] [Google Scholar]
106. Hay CW, Sinclair EM, Bermano G, Durward E, Tadayyon M, Docherty K. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. J Endocrinol. 2005;186(2):353–65. [PubMed] [Google Scholar]
107. Foulkes NS, Sassone-Corsi P. Transcription factors coupled to the cAMP-signalling pathway. Biochim Biophys Acta. 1996;1288(3):F101–21. [PubMed] [Google Scholar]
108. Metallo SJ, Paolella DN, Schepartz A. The role of a basic amino acid cluster in target site selection and non-specific binding of bZIP peptides to DNA. Nucleic Acids Res. 1997;25(15):2967–72. [PMC free article] [PubMed] [Google Scholar]
109. Emens LA, Landers DW, Moss LG. Hepatocyte nuclear factor 1 alpha is expressed in a hamster insulinoma line and transactivates the rat insulin I gene. Proc Natl Acad Sci U S A. 1992;89(16):7300–4. [PMC free article] [PubMed] [Google Scholar]
110. Peng SY, Wang WP, Meng J, Li T, Zhang H, Li YM, Chen P, Ma KT, Zhou CY. ISL1 physically interacts with BETA2 to promote insulin gene transcriptional synergy in non-beta cells. Biochim Biophys Acta. 2005;1731(3):154–9. [PubMed] [Google Scholar]
111. Ohneda K, Mirmira RG, Wang J, Johnson JD, German MS. The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol. 2000;20(3):900–11. [PMC free article] [PubMed] [Google Scholar]
112. Suckale J, Solimena M. Pancreas islets in metabolic signaling--focus on the beta-cell. Front Biosci. 2008;13:7156–71. [PubMed] [Google Scholar]
113. Vander Mierde D, Scheuner D, Quintens R, Patel R, Song B, Tsukamoto K, Beullens M, Kaufman RJ, Bollen M, Schuit FC. Glucose activates a protein phosphatase-1-mediated signaling pathway to enhance overall translation in pancreatic beta-cells. Endocrinology. 2007;148(2):609–17. [PubMed] [Google Scholar]
114. Elouil H, Bensellam M, Guiot Y, Vander Mierde D, Pascal SM, Schuit FC, Jonas JC. Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets. Diabetologia. 2007;50(7):1442–52. [PubMed] [Google Scholar]
115. Wicksteed B, Uchizono Y, Alarcon C, McCuaig JF, Shalev A, Rhodes CJ. A cis-element in the 5′ untranslated region of the preproinsulin mRNA (ppIGE) is required for glucose regulation of proinsulin translation. Cell Metab. 2007;5(3):221–7. [PubMed] [Google Scholar]
116. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol. 1998;18(12):7499–509. [PMC free article] [PubMed] [Google Scholar]
117. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099–108. [PubMed] [Google Scholar]
118. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk−/− mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001;7(6):1153–63. [PubMed] [Google Scholar]
119. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, Kaufman RJ. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell. 2001;7(6):1165–76. [PubMed] [Google Scholar]
120. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000;25(4):406–9. [PubMed] [Google Scholar]
121. Zhang W, Feng D, Li Y, Iida K, McGrath B, Cavener DR. PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab. 2006;4(6):491–7. [PubMed] [Google Scholar]
122. Fonseca SG, Fukuma M, Lipson KL, Nguyen LX, Allen JR, Oka Y, Urano F. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem. 2005;280(47):39609–15. [PubMed] [Google Scholar]
123. Pirot P, Naamane N, Libert F, Magnusson NE, Orntoft TF, Cardozo AK, Eizirik DL. Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs. Diabetologia. 2007;50(5):1006–14. [PubMed] [Google Scholar]
124. Ortsater H, Sjoholm A. A busy cell--endoplasmic reticulum stress in the pancreatic beta-cell. Mol Cell Endocrinol. 2007;277(1–2):1–5. [PubMed] [Google Scholar]
125. Varadi A, Tsuboi T, Johnson-Cadwell LI, Allan VJ, Rutter GA. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 beta-cells. Biochem Biophys Res Commun. 2003;311(2):272–82. [PubMed] [Google Scholar]
126. Ort T, Maksimova E, Dirkx R, Kachinsky AM, Berghs S, Froehner SC, Solimena M. The receptor tyrosine phosphatase-like protein ICA512 binds the PDZ domains of beta2-syntrophin and nNOS in pancreatic beta-cells. Eur J Cell Biol. 2000;79(9):621–30. [PubMed] [Google Scholar]
127. Mziaut H, Trajkovski M, Kersting S, Ehninger A, Altkruger A, Lemaitre RP, Schmidt D, Saeger HD, Lee MS, Drechsel DN, Muller S, Solimena M. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol. 2006;8(5):435–45. [PubMed] [Google Scholar]
128. Itoh N, Okamoto H. Translational control of proinsulin synthesis by glucose. Nature. 1980;283(5742):100–2. [PubMed] [Google Scholar]
129. Permutt MA, Kipnis DM. Insulin biosynthesis. I. On the mechanism of glucose stimulation. J Biol Chem. 1972;247(4):1194–9. [PubMed] [Google Scholar]
130. Izquierdo JM, Majos N, Bonnal S, Martinez C, Castelo R, Guigo R, Bilbao D, Valcarcel J. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell. 2005;19(4):475–84. [PubMed] [Google Scholar]
131. Spellman R, Smith CW. Novel modes of splicing repression by PTB. Trends Biochem Sci. 2006;31(2):73–6. [PubMed] [Google Scholar]
132. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell. 2004;13(1):91–100. [PubMed] [Google Scholar]
133. Schmitz O, Rungby J, Edge L, Juhl CB. On high-frequency insulin oscillations. Ageing Res Rev. 2008;7(4):301–5. [PubMed] [Google Scholar]
134. Chang TW, Goldberg AL. The metabolic fates of amino acids and the formation of glutamine in skeletal muscle. J Biol Chem. 1978;253(10):3685–93. [PubMed] [Google Scholar]
135. Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature. 1999;402(6762):685–9. [PubMed] [Google Scholar]
136. Eto K, Tsubamoto Y, Terauchi Y, Sugiyama T, Kishimoto T, Takahashi N, Yamauchi N, Kubota N, Murayama S, Aizawa T, Akanuma Y, Aizawa S, Kasai H, Yazaki Y, Kadowaki T. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Science. 1999;283(5404):981–5. [PubMed] [Google Scholar]
137. Bender K, Newsholme P, Brennan L, Maechler P. The importance of redox shuttles to pancreatic beta-cell energy metabolism and function. Biochem Soc Trans. 2006;34(Pt 5):811–4. [PubMed] [Google Scholar]
138. Sener A, Malaisse WJ. L-leucine and a nonmetabolized analogue activate pancreatic islet glutamate dehydrogenase. Nature. 1980;288(5787):187–9. [PubMed] [Google Scholar]
139. Dixon G, Nolan J, McClenaghan N, Flatt PR, Newsholme P. A comparative study of amino acid consumption by rat islet cells and the clonal beta-cell line BRIN-BD11 - the functional significance of L-alanine. J Endocrinol. 2003;179(3):447–54. [PubMed] [Google Scholar]
140. Tang-Christensen M, Larsen PJ, Thulesen J, Nielsen JR, Vrang N. Glucagon-like peptide 2, a neurotransmitter with a newly discovered role in the regulation of food ingestion. Ugeskr Laeger. 2001;163(3):287–91. [PubMed] [Google Scholar]
141. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51 (Suppl 3):S434–42. [PubMed] [Google Scholar]
142. MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes. 2002;51 (Suppl 3):S443–7. [PubMed] [Google Scholar]
143. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51(1):7–18. [PubMed] [Google Scholar]
144. Nolan CJ, Leahy JL, Delghingaro-Augusto V, Moibi J, Soni K, Peyot ML, Fortier M, Guay C, Lamontagne J, Barbeau A, Przybytkowski E, Joly E, Masiello P, Wang S, Mitchell GA, Prentki M. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia. 2006;49(9):2120–30. [PubMed] [Google Scholar]
145. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes. 2002;51 (Suppl 3):S405–13. [PubMed] [Google Scholar]
146. Crespin SR, Greenough WB, 3rd, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest. 1969;48(10):1934–43. [PMC free article] [PubMed] [Google Scholar]
147. Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes. 2004;53(4):1007–19. [PubMed] [Google Scholar]
148. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest. 1996;97(12):2728–35. [PMC free article] [PubMed] [Google Scholar]
149. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR, Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303–11. [PubMed] [Google Scholar]
150. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422(6928):173–6. [PubMed] [Google Scholar]
151. Prentki M. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur J Endocrinol. 1996;134(3):272–86. [PubMed] [Google Scholar]
152. Chapman ER, Blasi J, An S, Brose N, Johnston PA, Sudhof TC, Jahn R. Fatty acylation of synaptotagmin in PC12 cells and synaptosomes. Biochem Biophys Res Commun. 1996;225(1):326–32. [PubMed] [Google Scholar]
153. Gonzalo S, Linder ME. SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory pathway. Mol Biol Cell. 1998;9(3):585–97. [PMC free article] [PubMed] [Google Scholar]
154. Prentki M, Matschinsky FM. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev. 1987;67(4):1185–248. [PubMed] [Google Scholar]
155. Rhee JS, Betz A, Pyott S, Reim K, Varoqueaux F, Augustin I, Hesse D, Sudhof TC, Takahashi M, Rosenmund C, Brose N. Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs. Cell. 2002;108(1):121–33. [PubMed] [Google Scholar]
156. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52(10):2461–74. [PubMed] [Google Scholar]
157. Salehi A, Fan BG, Ekelund M, Nordin G, Lundquist I. TPN-evoked dysfunction of islet lysosomal activity mediates impairment of glucose-stimulated insulin release. Am J Physiol Endocrinol Metab. 2001;281(1):E171–9. [PubMed] [Google Scholar]
158. Schulla V, Renstrom E, Feil R, Feil S, Franklin I, Gjinovci A, Jing XJ, Laux D, Lundquist I, Magnuson MA, Obermuller S, Olofsson CS, Salehi A, Wendt A, Klugbauer N, Wollheim CB, Rorsman P, Hofmann F. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1. 2 Ca2+ channel null mice. Embo J. 2003;22(15):3844–54. [PMC free article] [PubMed] [Google Scholar]
159. Bratanova-Tochkova TK, Cheng H, Daniel S, Gunawardana S, Liu YJ, Mulvaney-Musa J, Schermerhorn T, Straub SG, Yajima H, Sharp GW. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes. 2002;51 (Suppl 1):S83–90. [PubMed] [Google Scholar]
160. Straub SG, Sharp GW. Hypothesis: one rate-limiting step controls the magnitude of both phases of glucose-stimulated insulin secretion. Am J Physiol Cell Physiol. 2004;287(3):C565–71. [PubMed] [Google Scholar]
161. Olofsson CS, Gopel SO, Barg S, Galvanovskis J, Ma X, Salehi A, Rorsman P, Eliasson L. Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells. Pflugers Arch. 2002;444(1–2):43–51. [PubMed] [Google Scholar]
162. Daniel S, Noda M, Straub SG, Sharp GW. Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Diabetes. 1999;48(9):1686–90. [PubMed] [Google Scholar]
163. Kang L, He Z, Xu P, Fan J, Betz A, Brose N, Xu T. Munc13-1 is required for the sustained release of insulin from pancreatic beta cells. Cell Metab. 2006;3(6):463–8. [PubMed] [Google Scholar]
164. Kwan EP, Xie L, Sheu L, Nolan CJ, Prentki M, Betz A, Brose N, Gaisano HY. Munc13-1 deficiency reduces insulin secretion and causes abnormal glucose tolerance. Diabetes. 2006;55(5):1421–9. [PubMed] [Google Scholar]
165. Gerst JE. SNARE regulators: matchmakers and matchbreakers. Biochim Biophys Acta. 2003;1641(2–3):99–110. [PubMed] [Google Scholar]
166. Hatsuzawa K, Lang T, Fasshauer D, Bruns D, Jahn R. The R-SNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis. J Biol Chem. 2003;278(33):31159–66. [PubMed] [Google Scholar]
167. Cheviet S, Bezzi P, Ivarsson R, Renstrom E, Viertl D, Kasas S, Catsicas S, Regazzi R. Tomosyn-1 is involved in a post-docking event required for pancreatic beta-cell exocytosis. J Cell Sci. 2006;119(Pt 14):2912–20. [PubMed] [Google Scholar]
168. Yizhar O, Matti U, Melamed R, Hagalili Y, Bruns D, Rettig J, Ashery U. Tomosyn inhibits priming of large dense-core vesicles in a calcium-dependent manner. Proc Natl Acad Sci U S A. 2004;101(8):2578–83. [PMC free article] [PubMed] [Google Scholar]
169. Gauthier BR, Wollheim CB. Synaptotagmins bind calcium to release insulin. Am J Physiol Endocrinol Metab. 2008;295(6):E1279–86. [PubMed] [Google Scholar]
170. Eliasson L, Ma X, Renstrom E, Barg S, Berggren PO, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S, Rorsman P. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol. 2003;121(3):181–97. [PMC free article] [PubMed] [Google Scholar]
171. Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, Tajima N, Iwanaga T, Seino S. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem. 2002;277(52):50497–502. [PubMed] [Google Scholar]
172. Catterall WA. Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release. Cell Calcium. 1998;24(5–6):307–23. [PubMed] [Google Scholar]
173. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521–55. [PubMed] [Google Scholar]
174. Dolphin AC. L-type calcium channel modulation. Adv Second Messenger Phosphoprotein Res. 1999;33:153–77. [PubMed] [Google Scholar]
175. Reid CA, Bekkers JM, Clements JD. Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci. 2003;26(12):683–7. [PubMed] [Google Scholar]
176. Heady TN, Gomora JC, Macdonald TL, Perez-Reyes E. Molecular pharmacology of T-type Ca2+ channels. Jpn J Pharmacol. 2001;85(4):339–50. [PubMed] [Google Scholar]
177. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83(1):117–61. [PubMed] [Google Scholar]
178. Triggle DJ. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels. Am J Hypertens. 1998;11(4 Pt 3):80S–87S. [PubMed] [Google Scholar]
179. Jing X, Li DQ, Olofsson CS, Salehi A, Surve VV, Caballero J, Ivarsson R, Lundquist I, Pereverzev A, Schneider T, Rorsman P, Renstrom E. CaV2. 3 calcium channels control second-phase insulin release. J Clin Invest. 2005;115(1):146–54. [PMC free article] [PubMed] [Google Scholar]
180. Vajna R, Klockner U, Pereverzev A, Weiergraber M, Chen X, Miljanich G, Klugbauer N, Hescheler J, Perez-Reyes E, Schneider T. Functional coupling between ‘R-type’ Ca2+ channels and insulin secretion in the insulinoma cell line INS-1. Eur J Biochem. 2001;268(4):1066–75. [PubMed] [Google Scholar]
181. Vignali S, Leiss V, Karl R, Hofmann F, Welling A. Characterization of voltage-dependent sodium and calcium channels in mouse pancreatic A- and B-cells. J Physiol. 2006;572(Pt 3):691–706. [PMC free article] [PubMed] [Google Scholar]
182. Rorsman P, Trube G. Calcium and delayed potassium currents in mouse pancreatic beta-cells under voltage-clamp conditions. J Physiol. 1986;374:531–50. [PMC free article] [PubMed] [Google Scholar]
183. Gromada J, Hoy M, Renstrom E, Bokvist K, Eliasson L, Gopel S, Rorsman P. CaM kinase II-dependent mobilization of secretory granules underlies acetylcholine-induced stimulation of exocytosis in mouse pancreatic B-cells. J Physiol. 1999;518 ( Pt 3):745–59. [PMC free article] [PubMed] [Google Scholar]
184. Henquin JC. The interplay between cyclic AMP and ions in the stimulus-secretion coupling in pancreatic B-cells. Arch Int Physiol Biochim. 1985;93(1):37–48. [PubMed] [Google Scholar]
185. Malaisse WJ, Malaisse-Lagae F. The role of cyclic AMP in insulin release. Experientia. 1984;40(10):1068–74. [PubMed] [Google Scholar]
186. Sutherland EW, Robison GA. The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes. 1969;18(12):797–819. [PubMed] [Google Scholar]
187. Charles MA, Fanska R, Schmid FG, Forsham PH, Grodsky GM. Adenosine 3′,5′-monophosphate in pancreatic islets: glucose-induced insulin release. Science. 1973;179(73):569–71. [PubMed] [Google Scholar]
188. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142(2):521–7. [PubMed] [Google Scholar]
189. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept. 2002;107(1–3):1–13. [PubMed] [Google Scholar]
190. Jones PM, Persaud SJ. Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic beta-cells. Endocr Rev. 1998;19(4):429–61. [PubMed] [Google Scholar]
191. Renstrom E, Eliasson L, Rorsman P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol. 1997;502 ( Pt 1):105–18. [PMC free article] [PubMed] [Google Scholar]
192. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000;2(11):805–11. [PubMed] [Google Scholar]
193. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396(6710):474–7. [PubMed] [Google Scholar]
194. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate Rap1. Science. 1998;282(5397):2275–9. [PubMed] [Google Scholar]
195. Kang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, Bos JL, Schwede F, Coetzee WA, Holz GG. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J Physiol. 2006;573(Pt 3):595–609. [PMC free article] [PubMed] [Google Scholar]
196. Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, Tajima N, Iwanaga T, Seino S. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem. 2002;277(52):50497–502. [PubMed] [Google Scholar]
197. Wang Y, Okamoto M, Schmitz F, Hofmann K, Sudhof TC. Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion. Nature. 1997;388(6642):593–8. [PubMed] [Google Scholar]
198. Gundelfinger ED, Kessels MM, Qualmann B. Temporal and spatial coordination of exocytosis and endocytosis. Nat Rev Mol Cell Biol. 2003;4(2):127–39. [PubMed] [Google Scholar]
199. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem. 2000;275(27):20829–36. [PubMed] [Google Scholar]
200. Kuno T, Shuntoh H, Sakaue M, Saijoh K, Takeda T, Fukuda K, Tanaka C. Site-directed mutagenesis of the cAMP-binding sites of the recombinant type I regulatory subunit of cAMP-dependentprotein kinase. Biochem Biophys Res Commun. 1988;153(3):1244–50. [PubMed] [Google Scholar]
201. Ringheim GE, Taylor SS. Effects of cAMP-binding site mutations on intradomain cross-communication in the regulatory subunit of cAMP-dependent protein kinase I. J Biol Chem. 1990;265(32):19472–8. [PubMed] [Google Scholar]
202. Stark JM, Jasin M. Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. Mol Cell Biol. 2003;23(2):733–43. [PMC free article] [PubMed] [Google Scholar]
203. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S. Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem. 2001;276(49):46046–53. [PubMed] [Google Scholar]
204. Nakazaki M, Crane A, Hu M, Seghers V, Ullrich S, Aguilar-Bryan L, Bryan J. cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes. 2002;51(12):3440–9. [PubMed] [Google Scholar]
205. Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem. 2002;277(40):37176–83. [PubMed] [Google Scholar]
206. Schmidt M, Evellin S, Weernink PA, von Dorp F, Rehmann H, Lomasney JW, Jakobs KH. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol. 2001;3(11):1020–4. [PubMed] [Google Scholar]
207. Shibasaki T, Sunaga Y, Seino S. Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis. Diabetes. 2004;53 (Suppl 3):S59–62. [PubMed] [Google Scholar]
208. Barg S, Huang P, Eliasson L, Nelson DJ, Obermuller S, Rorsman P, Thevenod F, Renstrom E. Priming of insulin granules for exocytosis by granular Cl(−) uptake and acidification. J Cell Sci. 2001;114(Pt 11):2145–54. [PubMed] [Google Scholar]
209. Kang G, Chepurny OG, Holz GG. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol. 2001;536(Pt 2):375–85. [PMC free article] [PubMed] [Google Scholar]
210. Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, Bos JL, Schwede F, Genieser HG, Holz GG. Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem. 2003;278(10):8279–85. [PMC free article] [PubMed] [Google Scholar]
211. Bode HP, Moormann B, Dabew R, Goke B. Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A. Endocrinology. 1999;140(9):3919–27. [PubMed] [Google Scholar]
212. Kang G, Chepurny OG, Rindler MJ, Collis L, Chepurny Z, Li WH, Harbeck M, Roe MW, Holz GG. A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells. J Physiol. 2005;566(Pt 1):173–88. [PMC free article] [PubMed] [Google Scholar]
213. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol. 2006;577(Pt 1):5–15. [PMC free article] [PubMed] [Google Scholar]
214. Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci U S A. 2000;97(21):11603–8. [PMC free article] [PubMed] [Google Scholar]
215. Sutter-Dub MT. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids. 2002;67(2):77–93. [PubMed] [Google Scholar]
216. Nadal A, Rovira JM, Laribi O, Leon-quinto T, Andreu E, Ripoll C, Soria B. Rapid insulinotropic effect of 17beta-estradiol via a plasma membrane receptor. FASEB J. 1998;12(13):1341–8. [PubMed] [Google Scholar]
217. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs. 1994;47 (Suppl 2):35–41. [PubMed] [Google Scholar]
218. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997;40(7):843–9. [PubMed] [Google Scholar]
219. Ropero AB, Soria B, Nadal A. A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. Mol Endocrinol. 2002;16(3):497–505. [PubMed] [Google Scholar]
220. Hawkins MB, Thornton JW, Crews D, Skipper JK, Dotte A, Thomas P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc Natl Acad Sci U S A. 2000;97(20):10751–6. [PMC free article] [PubMed] [Google Scholar]
221. Ropero AB, Fuentes E, Rovira JM, Ripoll C, Soria B, Nadal A. Non-genomic actions of 17beta-oestradiol in mouse pancreatic beta-cells are mediated by a cGMP-dependent protein kinase. J Physiol. 1999;521(Pt 2):397–407. [PMC free article] [PubMed] [Google Scholar]
222. Sheng M, McFadden G, Greenberg ME. Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron. 1990;4(4):571–82. [PubMed] [Google Scholar]
223. Cartin L, Lounsbury KM, Nelson MT. Coupling of Ca(2+) to CREB activation and gene expression in intact cerebral arteries from mouse : roles of ryanodine receptors and voltage-dependent Ca(2+) channels. CircRes. 2000;86(7):760–7. [PubMed] [Google Scholar]
224. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821–61. [PubMed] [Google Scholar]
225. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2(8):599–609. [PubMed] [Google Scholar]
226. Arendt J. Melatonin and the mammalian pineal gland. Chapman and Hall; London: 1994. [Google Scholar]
227. Peschke E, Muhlbauer E, Musshoff U, Csernus VJ, Chankiewitz E, Peschke D. Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res. 2002;33(2):63–71. [PubMed] [Google Scholar]
228. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol. 2002;191(2):157–66. [PubMed] [Google Scholar]
229. Ramracheya RD, Muller DS, Squires PE, Brereton H, Sugden D, Huang GC, Amiel SA, Jones PM, Persaud SJ. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res. 2008;44(3):273–9. [PubMed] [Google Scholar]
230. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res. 2008;44(1):26–40. [PubMed] [Google Scholar]
231. Bailey CJ, Atkins TW, Matty AJ. Melatonin inhibition of insulin secretion in the rat and mouse. Horm Res. 1974;5(1):21–8. [PubMed] [Google Scholar]
232. Frankel BJ, Strandberg MJ. Insulin release from isolated mouse islets in vitro: no effect of physiological levels of melatonin or arginine vasotocin. J Pineal Res. 1991;11(3–4):145–8. [PubMed] [Google Scholar]
233. Peschke E, Bach AG, Muhlbauer E. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res. 2006;40(2):184–91. [PubMed] [Google Scholar]
234. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, Bugliani M, Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, Mulder H, Groop L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8. [PMC free article] [PubMed] [Google Scholar]
235. Peschke E, Peschke D, Hammer T, Csernus V. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro. J Pineal Res. 1997;23(3):156–63. [PubMed] [Google Scholar]
236. Picinato MC, Haber EP, Cipolla-Neto J, Curi R, de Oliveira Carvalho CR, Carpinelli AR. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J Pineal Res. 2002;33(3):156–60. [PubMed] [Google Scholar]
237. Nishida S, Segawa T, Murai I, Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res. 2002;32(1):26–33. [PubMed] [Google Scholar]
238. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309(1):151–62. [PubMed] [Google Scholar]
239. Petit L, Lacroix I, de Coppet P, Strosberg AD, Jockers R. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol. 1999;58(4):633–9. [PubMed] [Google Scholar]
240. Bach AG, Wolgast S, Muhlbauer E, Peschke E. Melatonin stimulates inositol-1,4,5-trisphosphate and Ca2+ release from INS1 insulinoma cells. J Pineal Res. 2005;39(3):316–23. [PubMed] [Google Scholar]
241. Godson C, Reppert SM. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology. 1997;138(1):397–404. [PubMed] [Google Scholar]
242. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 1992;35(8):701–11. [PubMed] [Google Scholar]
243. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–20. [PMC free article] [PubMed] [Google Scholar]
244. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. JClin Endocrinol Metab. 1993;76(4):912–7. [PubMed] [Google Scholar]
245. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8(5):369–85. [PubMed] [Google Scholar]
246. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546–93. [PMC free article] [PubMed] [Google Scholar]
247. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. [PubMed] [Google Scholar]
248. Rossetti L, Massillon D, Barzilai N, Vuguin P, Chen W, Hawkins M, Wu J, Wang J. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem. 1997;272(44):27758–63. [PubMed] [Google Scholar]
249. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O’Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903–8. [PubMed] [Google Scholar]
250. Fehmann HC, Peiser C, Bode HP, Stamm M, Staats P, Hedetoft C, Lang RE, Goke B. Leptin: a potent inhibitor of insulin secretion. Peptides. 1997;18(8):1267–73. [PubMed] [Google Scholar]
251. Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers DJ, Gardiner JV, Bailey CJ, Bloom SR. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest. 1997;100(11):2729–36. [PMC free article] [PubMed] [Google Scholar]
252. Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest. 1998;102(5):869–73. [PMC free article] [PubMed] [Google Scholar]
253. Chen NG, Swick AG, Romsos DR. Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. J Clin Invest. 1997;100(5):1174–9. [PMC free article] [PubMed] [Google Scholar]
254. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46(2):313–6. [PubMed] [Google Scholar]
255. Ishida K, Murakami T, Mizuno A, Iida M, Kuwajima M, Shima K. Leptin suppresses basal insulin secretion from rat pancreatic islets. Regul Pept. 1997;70(2–3):179–82. [PubMed] [Google Scholar]
256. Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes. 1997;46(6):1087–93. [PMC free article] [PubMed] [Google Scholar]
257. Ookuma M, Ookuma K, York DA. Effects of leptin on insulin secretion from isolated rat pancreatic islets. Diabetes. 1998;47(2):219–23. [PubMed] [Google Scholar]
258. Poitout V, Rouault C, Guerre-Millo M, Briaud I, Reach G. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans. Endocrinology. 1998;139(3):822–6. [PubMed] [Google Scholar]
259. Seufert J, Kieffer TJ, Habener JF. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A. 1999;96(2):674–9. [PMC free article] [PubMed] [Google Scholar]
260. Fehmann HC, Berghofer P, Brandhorst D, Brandhorst H, Hering B, Bretzel RG, Goke B. Leptin inhibition of insulin secretion from isolated human islets. Acta Diabetol. 1997;34(4):249–52. [PubMed] [Google Scholar]
261. Lupi R, Marchetti P, Maffei M, Del Guerra S, Benzi L, Marselli L, Bertacca A, Navalesi R. Effects of acute or prolonged exposure to human leptin on isolated human islet function. Biochem Biophys Res Commun. 1999;256(3):637–41. [PubMed] [Google Scholar]
262. Fehmann HC, Bode HP, Ebert T, Karl A, Goke B. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction. Horm Metab Res. 1997;29(11):572–6. [PubMed] [Google Scholar]
263. Ahren B, Havel PJ. Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells) Am J Physiol. 1999;277(4 Pt 2):R959–66. [PubMed] [Google Scholar]
264. Sonksen PH. Insulin, growth hormone and sport. J Endocrinol. 2001;170(1):13–25. [PubMed] [Google Scholar]
265. Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989;86(8):2868–72. [PMC free article] [PubMed] [Google Scholar]
266. Van Schravendijk CF, Heylen L, Van den Brande JL, Pipeleers DG. Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic beta cells. Diabetologia. 1990;33(11):649–53. [PubMed] [Google Scholar]
267. Zhang F, Sjoholm K, Zhang Q. Attenuation of insulin secretion by insulin-like growth factor binding protein-1 in pancreatic beta-cells. Biochem Biophys Res Commun. 2007;362(1):152–7. [PubMed] [Google Scholar]
268. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 (Suppl 2):S97–107. [PubMed] [Google Scholar]
269. Sparre T, Larsen MR, Heding PE, Karlsen AE, Jensen ON, Pociot F. Unraveling the pathogenesis of type 1 diabetes with proteomics: present and future directions. Mol Cell Proteomics. 2005;4(4):441–57. [PubMed] [Google Scholar]
270. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007;7(12):988–94. [PubMed] [Google Scholar]
271. Tisch R, Wang B. Dysrulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol. 2008;100:125–49. [PubMed] [Google Scholar]
272. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol. 2008;100:79–124. [PubMed] [Google Scholar]
273. Mandrup-Poulsen T, Helqvist S, Molvig J, Wogensen LD, Nerup J. Cytokines as immune effector molecules in autoimmune endocrine diseases with special reference to insulin-dependent diabetes mellitus. Autoimmunity. 1989;4(3):191–218. discussion 219–34. [PubMed] [Google Scholar]
274. Pankewycz OG, Guan JX, Benedict JF. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev. 1995;16(2):164–76. [PubMed] [Google Scholar]
275. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol. 1998;55(8):1139–49. [PubMed] [Google Scholar]
276. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia. 2003;46(2):255–66. [PubMed] [Google Scholar]
277. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48(7):1339–49. [PubMed] [Google Scholar]
278. Thomas HE, Darwiche R, Corbett JA, Kay TW. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes. 2002;51(2):311–6. [PubMed] [Google Scholar]
279. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML. Interleukin-1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology. 1995;136(11):4790–5. [PubMed] [Google Scholar]
280. Takamura T, Kato I, Kimura N, Nakazawa T, Yonekura H, Takasawa S, Okamoto H. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J Biol Chem. 1998;273(5):2493–6. [PubMed] [Google Scholar]
281. Lindsay RM, Smith W, Rossiter SP, McIntyre MA, Williams BC, Baird JD. N omega-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes. 1995;44(3):365–8. [PubMed] [Google Scholar]
282. Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J Biol Chem. 1997;272(21):13697–704. [PubMed] [Google Scholar]
283. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes. 1999;48(4):706–13. [PubMed] [Google Scholar]
284. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res. 2004;36(11–12):811–21. [PubMed] [Google Scholar]
285. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51(5):1443–52. [PubMed] [Google Scholar]
286. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45(1):85–96. [PubMed] [Google Scholar]
287. Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, Bugliani M, Boggi U, Vistoli F, Mosca F, Del Prato S. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–41. [PubMed] [Google Scholar]
288. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 1999;48(5):989–96. [PubMed] [Google Scholar]
289. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 2005;54(9):2596–601. [PubMed] [Google Scholar]
290. Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes. 2004;53(7):1700–5. [PubMed] [Google Scholar]
291. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57(12):3281–8. [PMC free article] [PubMed] [Google Scholar]
292. Eizirik DL, Mandrup-Poulsen T. A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia. 2001;44(12):2115–33. [PubMed] [Google Scholar]
293. Hostens K, Pavlovic D, Zambre Y, Ling Z, Van Schravendijk C, Eizirik DL, Pipeleers DG. Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. J Clin Invest. 1999;104(1):67–72. [PMC free article] [PubMed] [Google Scholar]
294. Eizirik DL, Kutlu B, Rasschaert J, Darville M, Cardozo AK. Use of microarray analysis to unveil transcription factor and gene networks contributing to Beta cell dysfunction and apoptosis. Ann N Y Acad Sci. 2003;1005:55–74. [PubMed] [Google Scholar]
295. Norlin S, Ahlgren U, Edlund H. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes. 2005;54(1):125–32. [PubMed] [Google Scholar]
296. Darville MI, Eizirik DL. Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia. 1998;41(9):1101–8. [PubMed] [Google Scholar]
297. Andersson AK, Borjesson A, Sandgren J, Sandler S. Cytokines affect PDX-1 expression, insulin and proinsulin secretion from iNOS deficient murine islets. Mol Cell Endocrinol. 2005;240(1–2):50–7. [PubMed] [Google Scholar]
298. Cardozo AK, Kruhoffer M, Leeman R, Orntoft T, Eizirik DL. Identification of novel cytokine-induced genes in pancreatic beta-cells by high-density oligonucleotide arrays. Diabetes. 2001;50(5):909–20. [PubMed] [Google Scholar]
299. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia. 2001;44(3):325–32. [PubMed] [Google Scholar]
300. Kutlu B, Darville MI, Cardozo AK, Eizirik DL. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes. 2003;52(2):348–55. [PubMed] [Google Scholar]
301. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, Orntoft T, Eizirik DL. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem. 2001;276(52):48879–86. [PubMed] [Google Scholar]
302. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29(1):42–61. [PubMed] [Google Scholar]
303. Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, Wada I, Akira S, Araki E, Mori M. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A. 2001;98(19):10845–50. [PMC free article] [PubMed] [Google Scholar]
304. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis. 2002;7(4):335–45. [PubMed] [Google Scholar]
305. Ammendrup A, Maillard A, Nielsen K, Aabenhus Andersen N, Serup P, Dragsbaek Madsen O, Mandrup-Poulsen T, Bonny C. The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes. 2000;49(9):1468–76. [PubMed] [Google Scholar]
306. Negri S, Oberson A, Steinmann M, Sauser C, Nicod P, Waeber G, Schorderet DF, Bonny C. cDNA cloning and mapping of a novel islet-brain/JNK-interacting protein. Genomics. 2000;64(3):324–30. [PubMed] [Google Scholar]
307. Ferdaoussi M, Abdelli S, Yang JY, Cornu M, Niederhauser G, Favre D, Widmann C, Regazzi R, Thorens B, Waeber G, Abderrahmani A. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes. 2008;57(5):1205–15. [PubMed] [Google Scholar]
308. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes. 2001;50(1):77–82. [PubMed] [Google Scholar]
309. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47(3):581–9. [PubMed] [Google Scholar]
310. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes. 2001;50 (Suppl 1):S154–9. [PubMed] [Google Scholar]
311. Zhou YP, Marlen K, Palma JF, Schweitzer A, Reilly L, Gregoire FM, Xu GG, Blume JE, Johnson JD. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? J Biol Chem. 2003;278(51):51316–23. [PubMed] [Google Scholar]
312. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52(3):581–7. [PubMed] [Google Scholar]
313. Elouil H, Cardozo AK, Eizirik DL, Henquin JC, Jonas JC. High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NFkappaB. Diabetologia. 2005;48(3):496–505. [PubMed] [Google Scholar]
314. Gurgul E, Lortz S, Tiedge M, Jorns A, Lenzen S. Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. Diabetes. 2004;53(9):2271–80. [PubMed] [Google Scholar]
315. Fridlyand LE, Philipson LH. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes. 2004;53(8):1942–8. [PubMed] [Google Scholar]
316. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes. 2001;50 (Suppl 1):S122–4. [PubMed] [Google Scholar]
317. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes. 2003;52(3):726–33. [PubMed] [Google Scholar]
318. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes. 2001;50(1):69–76. [PubMed] [Google Scholar]
319. Kharroubi I, Ladriere L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology. 2004;145(11):5087–96. [PubMed] [Google Scholar]
320. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes. 2001;50(8):1771–7. [PubMed] [Google Scholar]
321. Rys-Sikora KE, Gill DL. Fatty acid-mediated calcium sequestration within intracellular calcium pools. J Biol Chem. 1998;273(49):32627–35. [PubMed] [Google Scholar]
322. Bonner-Weir S. beta-cell turnover: its assessment and implications. Diabetes. 2001;50 (Suppl 1):S20–4. [PubMed] [Google Scholar]
323. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47(3):358–64. [PubMed] [Google Scholar]
324. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res. 1985;4(2):110–25. [PubMed] [Google Scholar]
325. Buettner R, Newgard CB, Rhodes CJ, O’Doherty RM. Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by moderate hyperleptinemia. Am J Physiol Endocrinol Metab. 2000;278(3):E563–9. [PubMed] [Google Scholar]
326. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006;55(12):3238–45. [PubMed] [Google Scholar]
327. Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464(7292):1149–54. [PMC free article] [PubMed] [Google Scholar]
328. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol. 2000;24(3):297–302. [PubMed] [Google Scholar]
329. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B, Thomas G. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature. 2000;408(6815):994–7. [PubMed] [Google Scholar]
330. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest. 2002;32 (Suppl 3):3–13. [PubMed] [Google Scholar]
331. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem. 1998;273(28):17771–9. [PubMed] [Google Scholar]
332. Cousin SP, Hugl SR, Myers MG, Jr, White MF, Reifel-Miller A, Rhodes CJ. Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling. Biochem J. 1999;344(Pt 3):649–58. [PMC free article] [PubMed] [Google Scholar]
333. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes. 1999;48(4):738–44. [PubMed] [Google Scholar]
334. Galsgaard ED, Gouilleux F, Groner B, Serup P, Nielsen JH, Billestrup N. Identification of a growth hormone-responsive STAT5-binding element in the rat insulin 1 gene. Mol Endocrinol. 1996;10(6):652–60. [PubMed] [Google Scholar]
335. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology. 2004;145(9):4162–75. [PubMed] [Google Scholar]
336. Friedrichsen BN, Richter HE, Hansen JA, Rhodes CJ, Nielsen JH, Billestrup N, Moldrup A. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Mol Endocrinol. 2003;17(5):945–58. [PubMed] [Google Scholar]
337. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, Taketo MM, Nusse R, Hebrok M, Kim SK. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A. 2007;104(15):6247–52. [PMC free article] [PubMed] [Google Scholar]
338. Nielsen JH, Galsgaard ED, Moldrup A, Friedrichsen BN, Billestrup N, Hansen JA, Lee YC, Carlsson C. Regulation of beta-cell mass by hormones and growth factors. Diabetes. 2001;50 (Suppl 1):S25–9. [PubMed] [Google Scholar]
339. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell. 1997;88(4):561–72. [PubMed] [Google Scholar]
340. Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlein B, Furth EE, Polonsky KS, Naji A, Birnbaum MJ. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001;7(10):1133–7. [PubMed] [Google Scholar]
341. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15(5):314–22. [PubMed] [Google Scholar]
342. Dickson LM, Lingohr MK, McCuaig J, Hugl SR, Snow L, Kahn BB, Myers MG, Jr, Rhodes CJ. Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1) J Biol Chem. 2001;276(24):21110–20. [PubMed] [Google Scholar]
343. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 1999;68:965–1014. [PubMed] [Google Scholar]
344. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2(7892):1279–83. [PubMed] [Google Scholar]
345. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983;222(4630):1337–9. [PubMed] [Google Scholar]
346. Kuglin B, Gries FA, Kolb H. Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment. Diabetes. 1988;37(1):130–2. [PubMed] [Google Scholar]
347. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151–6. [PubMed] [Google Scholar]
348. Christie MR, Tun RY, Lo SS, Cassidy D, Brown TJ, Hollands J, Shattock M, Bottazzo GF, Leslie RD. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes. 1992;41(7):782–7. [PubMed] [Google Scholar]
349. Foulis AK, Farquharson MA, Hardman R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987;30(5):333–43. [PMC free article] [PubMed] [Google Scholar]
350. Root EJ, Combs GF., Jr Disruption of endoplasmic reticulum is the primary ultrastructural lesion of the pancreas in the selenium-deficient chick. Proc Soc Exp Biol Med. 1988;187(4):513–21. [PubMed] [Google Scholar]
351. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2(8499):119–24. [PubMed] [Google Scholar]
352. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA. 2003;290(13):1721–8. [PubMed] [Google Scholar]
353. Littorin B, Blom P, Scholin A, Arnqvist HJ, Blohme G, Bolinder J, Ekbom-Schnell A, Eriksson JW, Gudbjornsdottir S, Nystrom L, Ostman J, Sundkvist G. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS) Diabetologia. 2006;49(12):2847–52. [PubMed] [Google Scholar]
354. Frisk G, Hansson T, Dahlbom I, Tuvemo T. A unifying hypothesis on the development of type 1 diabetes and celiac disease: gluten consumption may be a shared causative factor. Med Hypotheses. 2008;70(6):1207–9. [PubMed] [Google Scholar]
355. Pugliese A. Genetics of type 1 diabetes. Endocrinol Metab Clin North Am. 2004;33(1):1–16. vii. [PubMed] [Google Scholar]
356. Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2010 [PMC free article] [PubMed] [Google Scholar]
357. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes. 1994;43(11):1304–10. [PubMed] [Google Scholar]
358. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001;108(9):1247–52. [PMC free article] [PubMed] [Google Scholar]
359. Wallet MA, Tisch R. Type 1 diabetes, inflammation and dendritic cells. Drug Discovery Today. 2006;3(3):373–379. [Google Scholar]
360. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev. 2008;7(7):550–7. [PubMed] [Google Scholar]
361. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003;46(3):305–21. [PubMed] [Google Scholar]
362. Guberski DL, Butler L, Kastern W, Like AA. Genetic studies in inbred BB/Wor rats. Analysis of progeny produced by crossing lymphopenic diabetes-prone rats with nonlymphopenic diabetic rats. Diabetes. 1989;38(7):887–93. [PubMed] [Google Scholar]
363. MacMurray AJ, Moralejo DH, Kwitek AE, Rutledge EA, Van Yserloo B, Gohlke P, Speros SJ, Snyder B, Schaefer J, Bieg S, Jiang J, Ettinger RA, Fuller J, Daniels TL, Pettersson A, Orlebeke K, Birren B, Jacob HJ, Lander ES, Lernmark A. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res. 2002;12(7):1029–39. [PMC free article] [PubMed] [Google Scholar]
365. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117(2):265–77. [PubMed] [Google Scholar]
366. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med. 2000;192(4):549–56. [PMC free article] [PubMed] [Google Scholar]
367. Isaacs JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, Waldmann H, Hale G, Hazleman BL. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum. 2001;44(9):1998–2008. [PubMed] [Google Scholar]
368. Thivolet C, Bendelac A, Bedossa P, Bach JF, Carnaud C. CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. J Immunol. 1991;146(1):85–8. [PubMed] [Google Scholar]
369. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol. 1995;15(3):121–9. [PubMed] [Google Scholar]
370. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73. [PubMed] [Google Scholar]
371. Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab. 1999;84(5):1497–502. [PubMed] [Google Scholar]
372. Bucy RP, Karr L, Huang GQ, Li J, Carter D, Honjo K, Lemons JA, Murphy KM, Weaver CT. Single cell analysis of cytokine gene coexpression during CD4+ T-cell phenotype development. Proc Natl Acad Sci U S A. 1995;92(16):7565–9. [PMC free article] [PubMed] [Google Scholar]
373. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol. 2003;4(9):835–42. [PubMed] [Google Scholar]
374. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science. 1995;268(5214):1185–8. [PubMed] [Google Scholar]
375. Liblau RS, Singer SM, McDevitt HO. Th2 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16(1):34–8. [PubMed] [Google Scholar]
376. Pilstrom B, Bjork L, Bohme J. Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th2-type cytokines characterize the effector phase. J Autoimmun. 1997;10(2):147–55. [PubMed] [Google Scholar]
377. Faust A, Rothe H, Schade U, Lampeter E, Kolb H. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation. 1996;62(5):648–52. [PubMed] [Google Scholar]
378. Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A. 1990;87(6):2239–43. [PMC free article] [PubMed] [Google Scholar]
379. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F, Jr, Dadufalza V, Buckingham BA. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol. 1996;157(10):4690–6. [PubMed] [Google Scholar]
380. Lee MS, Wogensen L, Shizuru J, Oldstone MB, Sarvetnick N. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest. 1994;93(3):1332–8. [PMC free article] [PubMed] [Google Scholar]
381. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997;186(2):229–38. [PMC free article] [PubMed] [Google Scholar]
382. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J, Ii S, Kudo E, Iwahana H, Hayashi Y, Sano T. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol. 1994;6(12):1927–36. [PubMed] [Google Scholar]
383. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th2 lineage commitment. Cell. 2000;100(6):655–69. [PubMed] [Google Scholar]
384. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med. 2002;195(9):1129–43. [PMC free article] [PubMed] [Google Scholar]
385. Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th2/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods. 2003;278(1–2):157–69. [PubMed] [Google Scholar]
386. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167(3):1137–40. [PubMed] [Google Scholar]
387. Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med. 2006;57:381–402. [PubMed] [Google Scholar]
388. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med. 2005;202(10):1387–97. [PMC free article] [PubMed] [Google Scholar]
389. Brusko T, Atkinson M. Treg in type 1 diabetes. Cell Biochem Biophys. 2007;48(2–3):165–75. [PubMed] [Google Scholar]
390. Filippi C, Bresson D, von Herrath M. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int Rev Immunol. 2005;24(5–6):341–60. [PubMed] [Google Scholar]
391. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med. 2002;196(3):369–77. [PMC free article] [PubMed] [Google Scholar]
392. McKenzie MD, Dudek NL, Mariana L, Chong MM, Trapani JA, Kay TW, Thomas HE. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol. 2006;18(6):837–46. [PubMed] [Google Scholar]
393. Shi L, Kraut RP, Aebersold R, Greenberg AH. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med. 1992;175(2):553–66. [PMC free article] [PubMed] [Google Scholar]
394. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A. 2003;100(26):15818–23. [PMC free article] [PubMed] [Google Scholar]
395. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000;12(7):1092–9. [PubMed] [Google Scholar]
396. Suzuki Y, Kuroda Y, Morita A, Fujino Y, Tanioka Y, Kawamura T, Saitoh Y. Fibrin glue sealing for the prevention of pancreatic fistulas following distal pancreatectomy. Arch Surg. 1995;130(9):952–5. [PubMed] [Google Scholar]
397. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, Kaplin AI, Nath A, Kerr DA, Calabresi PA. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008;196(1–2):124–32. [PubMed] [Google Scholar]
398. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th27 cells. J Exp Med. 2007;204(8):1849–61. [PMC free article] [PubMed] [Google Scholar]
399. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30(1):92–107. [PMC free article] [PubMed] [Google Scholar]
400. Vukkadapu SS, Belli JM, Ishii K, Jegga AG, Hutton JJ, Aronow BJ, Katz JD. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics. 2005;21(2):201–11. [PubMed] [Google Scholar]
401. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH, Yu P, Ellis JS, Hoeman CM, Franklin CL, Zaghouani H. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med. 2008;205(1):207–18. [PMC free article] [PubMed] [Google Scholar]
402. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, Takane KK, Garcia-Ocana A, Vasavada R, Stewart AF. Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr Rev. 2006;27(4):356–70. [PubMed] [Google Scholar]
403. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6. [PubMed] [Google Scholar]
404. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10. [PubMed] [Google Scholar]
405. Pietropaolo M, Le Roith D. Pathogenesis of diabetes: our current understanding. Clin Cornerstone. 2001;4(2):1–16. [PubMed] [Google Scholar]
406. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802–12. [PMC free article] [PubMed] [Google Scholar]
407. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307(5708):380–4. [PubMed] [Google Scholar]
408. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46(1):3–10. [PubMed] [Google Scholar]
409. Polonsky KS. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. 2000;24 (Suppl 2):S29–31. [PubMed] [Google Scholar]
410. Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci U S A. 2001;98(13):7475–80. [PMC free article] [PubMed] [Google Scholar]
411. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–65. [PubMed] [Google Scholar]
412. Van Citters GW, Kabir M, Kim SP, Mittelman SD, Dea MK, Brubaker PL, Bergman RN. Elevated glucagon-like peptide-1-(7–36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. J Clin Endocrinol Metab. 2002;87(11):5191–5198. [PubMed] [Google Scholar]
413. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40 (Suppl):S21–5. [PubMed] [Google Scholar]
414. Jaikaran ET, Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta. 2001;1537(3):179–203. [PubMed] [Google Scholar]
415. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim BiophysActa. 2010;1801(3):289–298. [PMC free article] [PubMed] [Google Scholar]
416. Poitout V. Glucolipotoxicity of the pancreatic beta-cell: myth or reality? Biochem Soc Trans. 2008;36(Pt 5):901–4. [PMC free article] [PubMed] [Google Scholar]
417. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29(3):351–66. [PMC free article] [PubMed] [Google Scholar]
418. Zhao NQ, Yu YR, Tan HW, Deng G, Zhang XX. Role of apoptosis and mitochondrial apoptotic pathway in glucolipotoxicity-induced islet beta-cell dysfunction. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(11):2009–13. [PubMed] [Google Scholar]
419. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218. [PubMed] [Google Scholar]
420. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord. 2008;9(4):329–343. [PMC free article] [PubMed] [Google Scholar]
421. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339–42. [PubMed] [Google Scholar]
422. Khaldi MZ, Guiot Y, Gilon P, Henquin JC, Jonas JC. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for 1 wk in high glucose. Am J Physiol Endocrinol Metab. 2004;287(2):E207–E217. [PubMed] [Google Scholar]
423. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110(6):851–60. [PMC free article] [PubMed] [Google Scholar]
424. Ohara-Imaizumi M, Cardozo AK, Kikuta T, Eizirik DL, Nagamatsu S. The cytokine interleukin-1 beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis. J Biol Chem. 2004;279(40):41271–41274. [PubMed] [Google Scholar]
425. Kajimoto Y, Matsuoka T, Kaneto H, Watada H, Fujitani Y, Kishimoto M, Sakamoto K, Matsuhisa M, Kawamori R, Yamasaki Y, Hori M. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia. 1999;42(12):1417–24. [PubMed] [Google Scholar]
426. Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology. 1997;138(1):273–80. [PubMed] [Google Scholar]
427. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A. 1999;96(19):10857–62. [PMC free article] [PubMed] [Google Scholar]
428. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki K, Hori M. Beneficial effects of antioxidants in diabetes - Possible protection of pancreatic beta-cells against glucose toxicity. Diabetes. 1999;48(12):2398–2406. [PubMed] [Google Scholar]
429. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H, Hiai H, Seino Y, Yamada Y. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes. 1999;48(4):927–32. [PubMed] [Google Scholar]
430. Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest. 1997;99(1):144–50. [PMC free article] [PubMed] [Google Scholar]
431. Kaneto H, Fujii J, Myint T, Miyazawa N, Islam KN, Kawasaki Y, Suzuki K, Nakamura M, Tatsumi H, Yamasaki Y, Taniguchi N. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J. 1996;320 ( Pt 3):855–63. [PMC free article] [PubMed] [Google Scholar]
432. Grankvist K, Marklund SL, Taljedal IB. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J. 1981;199(2):393–8. [PMC free article] [PubMed] [Google Scholar]
433. Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG. Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci U S A. 1982;79(3):927–30. [PMC free article] [PubMed] [Google Scholar]
434. Grankvist K, Marklund S, Taljedal IB. Superoxide dismutase is a prophylactic against alloxan diabetes. Nature. 1981;294(5837):158–60. [PubMed] [Google Scholar]
435. Tanaka Y, Tran PO, Harmon J, Robertson RP. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc Natl Acad Sci U S A. 2002;99(19):12363–8. [PMC free article] [PubMed] [Google Scholar]
436. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40(4):405–12. [PubMed] [Google Scholar]
437. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J. 1987;245(1):243–50. [PMC free article] [PubMed] [Google Scholar]
438. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J. 1988;256(1):205–12. [PMC free article] [PubMed] [Google Scholar]
439. Kaneto H, Xu G, Song KH, Suzuma K, Bonner-Weir S, Sharma A, Weir GC. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem. 2001;276(33):31099–104. [PubMed] [Google Scholar]
440. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem. 2002;277(33):30010–30018. [PubMed] [Google Scholar]
441. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391(6670):900–4. [PubMed] [Google Scholar]
442. Kubota N, Terauchi Y, Tobe K, Yano W, Suzuki R, Ueki K, Takamoto I, Satoh H, Maki T, Kubota T, Moroi M, Okada-Iwabu M, Ezaki O, Nagai R, Ueta Y, Kadowaki T, Noda T. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest. 2004;114(7):917–27. [PMC free article] [PubMed] [Google Scholar]
443. Bruning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 1997;17(3):1513–21. [PMC free article] [PubMed] [Google Scholar]
444. Martinez SC, Tanabe K, Cras-Meneur C, Abumrad NA, Bernal-Mizrachi E, Permutt MA. Inhibition of Foxol protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stress-induced apoptosis. Diabetes. 2008;57(4):846–859. [PubMed] [Google Scholar]
445. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84. [PubMed] [Google Scholar]
446. Mori H, Inoki K, Opland D, Muenzberg H, Villanueva EC, Faouzi M, Ikenoue T, Kwiatkowski D, Macdougald OA, Myers MG, Jr, Guan KL. Critical roles for the TSC-mTOR pathway in {beta}-cell function. Am J Physiol Endocrinol Metab. 2009 [PMC free article] [PubMed] [Google Scholar]
447. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10(3):457–468. [PubMed] [Google Scholar]
448. Briaud IM, Lingohr MK, Dickson LM, McCuaig JF, Lawrence JC, Rhodes CJ. IRS-2 proteasomal degradation mediated by a mTOR-induced negative feedback downregulates PKB-mediated signalling pathway in beta-cells. Diabetologia. 2004;47:A26–A26. [Google Scholar]
449. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17(13):1575–80. [PMC free article] [PubMed] [Google Scholar]
450. Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic Exposure of Hit Cells to High Glucose-Concentrations Paradoxically Decreases Insulin Gene-Transcription and Alters Binding of Insulin Gene Regulatory Protein. J Clin Invest. 1993;92(1):514–519. [PMC free article] [PubMed] [Google Scholar]
451. Park KG, Lee KM, Seo HY, Suh JH, Kim HS, Wang L, Won KC, Lee HW, Park JY, Lee KU, Kim JG, Kim BW, Choi HS, Lee IK. Glucotoxicity in the INS-1 rat insulinoma cell line is mediated by the orphan nuclear receptor small heterodimer partner. Diabetes. 2007;56(2):431–7. [PubMed] [Google Scholar]
452. Olson LK, Sharma A, Peshavaria M, Wright CVE, Towle HC, Robertson RP, Stein R. Reduction of Insulin Gene-Transcription in Hit-T15 Beta-Cells Chronically Exposed to a Supraphysiological Glucose-Concentration Is Associated with Loss of Stf-1 Transcription Factor Expression (Vol 92, Pg 9127, 1995) Proc Natl Acad Sci U S A. 1995;92(24):11322–11322. [PMC free article] [PubMed] [Google Scholar]
453. Sharma A, Olson LK, Robertson RP, Stein R. The Reduction of Insulin Gene-Transcription in Hit-T15 Beta-Cells Chronically Exposed to High Glucose-Concentration Is Associated with the Loss of Ripe3b1 and Stf-1 Transcription Factor Expression. Mol Endocrinol. 1995;9(9):1127–1134. [PubMed] [Google Scholar]
454. Poitout V, Olson LK, Robertson RP. Chronic exposure of beta TC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J Clin Invest. 1996;97(4):1041–1046. [PMC free article] [PubMed] [Google Scholar]
455. Lu M, Seufert J, Habener JF. Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT enhancer-binding protein beta - Inhibitory interactions with basic helix-loop-helix transcription factor E47. J Biol Chem. 1997;272(45):28349–28359. [PubMed] [Google Scholar]
456. Seufert J, Weir GC, Habener JF. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. J Clin Invest. 1998;101(11):2528–2539. [PMC free article] [PubMed] [Google Scholar]
457. Kharroubi I, Ladriere L, Cardozo AK, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic beta cell apoptosis by different mechanisms: role of NF-kappa B and endoplasmic reticulum stress. Diabetologia. 2004;47:A176–A176. [PubMed] [Google Scholar]
458. Eizirik DL. Interleukin-1 Induced Impairment in Pancreatic-Islet Oxidative-Metabolism of Glucose Is Potentiated by Tumor Necrosis Factor. Acta Endocrinologica. 1988;119(3):321–325. [PubMed] [Google Scholar]
459. Prentki M, Corkey BE. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 1996;45(3):273–83. [PubMed] [Google Scholar]
460. Roche E, Farfari S, Witters LA, Assimacopoulos-Jeannet F, Thumelin S, Brun T, Corkey BE, Saha AK, Prentki M. Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. Diabetes. 1998;47(7):1086–94. [PubMed] [Google Scholar]
461. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004;3(4):340–51. [PubMed] [Google Scholar]
462. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144(12):5179–83. [PubMed] [Google Scholar]
463. Salt IP, Johnson G, Ashcroft SJ, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J. 1998;335 ( Pt 3):533–9. [PMC free article] [PubMed] [Google Scholar]
464. Wang X, Zhou L, Li G, Luo T, Gu Y, Qian L, Fu X, Li F, Li J, Luo M. Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. Biochem Biophys Res Commun. 2007;352(2):463–8. [PubMed] [Google Scholar]
465. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366(Pt 2):377–91. [PMC free article] [PubMed] [Google Scholar]
466. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem. 1998;273(49):32487–90. [PubMed] [Google Scholar]
467. Moore PC, Ugas MA, Hagman DK, Parazzoli SD, Poitout V. Evidence against the involvement of oxidative stress in fatty acid inhibition of insulin secretion. Diabetes. 2004;53(10):2610–6. [PubMed] [Google Scholar]
468. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology. 2002;143(9):3449–53. [PubMed] [Google Scholar]
469. Sako Y, Grill VE. A 48-Hour Lipid Infusion in the Rat Time-Dependently Inhibits Glucose-Induced Insulin-Secretion and B-Cell Oxidation through a Process Likely Coupled to Fatty-Acid Oxidation. Endocrinology. 1990;127(4):1580–1589. [PubMed] [Google Scholar]
470. Elks ML. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology. 1993;133(1):208–14. [PubMed] [Google Scholar]
471. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab. 1995;80(5):1584–90. [PubMed] [Google Scholar]
472. Zhou YP, Grill VE. Long-Term Exposure of Rat Pancreatic-Islets to Fatty-Acids Inhibits Glucose-Induced Insulin-Secretion and Biosynthesis through a Glucose Fatty-Acid Cycle. J Clin Invest. 1994;93(2):870–876. [PMC free article] [PubMed] [Google Scholar]
473. Briaud I, Kelpe CL, Johnson LM, Tran PO, Poitout V. Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats. Diabetes. 2002;51(3):662–8. [PubMed] [Google Scholar]
474. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, Tsushima RG, Pennefather PS, Salapatek AM, Wheeler MB. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001;50(6):1302–10. [PubMed] [Google Scholar]
475. Schmitz-Peiffer C, Laybutt DR, Burchfield JG, Gurisik E, Narasimhan S, Mitchell CJ, Pedersen DJ, Braun U, Cooney GJ, Leitges M, Biden TJ. Inhibition of PKCepsilon improves glucose-stimulated insulin secretion and reduces insulin clearance. Cell Metab. 2007;6(4):320–8. [PubMed] [Google Scholar]
476. Olofsson CS, Collins S, Bengtsson M, Eliasson L, Salehi A, Shimomura K, Tarasov A, Holm C, Ashcroft F, Rorsman P. Long-term exposure to glucose and lipids inhibits glucose-induced insulin secretion downstream of granule fusion with plasma membrane. Diabetes. 2007;56(7):1888–97. [PubMed] [Google Scholar]
477. Hoppa MB, Collins S, Ramracheya R, Hodson L, Amisten S, Zhang Q, Johnson P, Ashcroft FM, Rorsman P. Chronic palmitate exposure inhibits insulin secretion by dissociation of Ca(2+) channels from secretory granules. Cell Metab. 2009;10(6):455–65. [PMC free article] [PubMed] [Google Scholar]
478. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–7. [PubMed] [Google Scholar]
479. Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U, Del Prato S, Rabuazzo AM, Purrello F, Marchetti P. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia. 2005;48(2):282–9. [PubMed] [Google Scholar]
480. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001;105(6):745–755. [PubMed] [Google Scholar]
481. Schiff M, Loublier S, Coulibaly A, Benit P, de Baulny HO, Rustin P. Mitochondria and diabetes mellitus: untangling a conflictive relationship? J Inherit Metab Dis. 2009;32(6):684–98. [PubMed] [Google Scholar]
482. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. Nature. 2001;414(6865):807–12. [PubMed] [Google Scholar]
483. Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, Lowell BB. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest. 2003;112(12):1831–42. [PMC free article] [PubMed] [Google Scholar]
484. Mulder H, Ling C. Mitochondrial dysfunction in pancreatic beta-cells in Type 2 diabetes. Mol Cell Endocrinol. 2009;297(1–2):34–40. [PubMed] [Google Scholar]
485. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, Cox RD. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia. 2005;48(4):675–86. [PubMed] [Google Scholar]
486. Freeman H, Shimomura K, Horner E, Cox RD, Ashcroft FM. Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab. 2006;3(1):35–45. [PubMed] [Google Scholar]
487. Trifunovic A, Larsson NG. Mitochondrial dysfunction as a cause of ageing. J Intern Med. 2008;263(2):167–178. [PubMed] [Google Scholar]
488. Seo HY, Kim YD, Lee KM, Min AK, Kim MK, Kim HS, Won KC, Park JY, Lee KU, Choi HS, Park KG, Lee IK. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. Endocrinology. 2008;149(8):3832–41. [PMC free article] [PubMed] [Google Scholar]
489. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell. 2000;101(5):451–4. [PubMed] [Google Scholar]
490. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999;10(11):3787–3799. [PMC free article] [PubMed] [Google Scholar]
491. Shen X, Zhang K, Kaufman RJ. The unfolded protein response--a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat. 2004;28(1–2):79–92. [PubMed] [Google Scholar]
492. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D. Chop (Gadd153) and Its Oncogenic Variant, Tls-Chop, Have Opposing Effects on the Induction of G(1)/S Arrest. Genes & Development. 1994;8(4):453–464. [PubMed] [Google Scholar]
493. Korennykh AV, Egea PF, Korostelev AA, Finer-Moore J, Zhang C, Shokat KM, Stroud RM, Walter P. The unfolded protein response signals through high-order assembly of Ire1. Nature. 2009;457(7230):687–U2. [PMC free article] [PubMed] [Google Scholar]
494. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics. 2011;10(2):52–60. [PubMed] [Google Scholar]
495. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet. 2007;8(9):657–62. [PubMed] [Google Scholar]
496. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley AT, Frayling TM. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6. 2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568–72. [PubMed] [Google Scholar]
497. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320–3. [PubMed] [Google Scholar]
498. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445(7130):881–5. [PubMed] [Google Scholar]
499. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316(5829):1341–5. [PMC free article] [PubMed] [Google Scholar]
500. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39(6):770–5. [PubMed] [Google Scholar]